Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Section 32 Information
Geographic Data
Address: -
City: Silicon Valley,
State: CA
Zip: 94024
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,606,848Website Global Rank
6,485Website Monthly Traffic
Twitter Followers
Description
Section 32, the new venture fund launched by Bill Maris, was named in homage to Section 31, an intelligence agency from the Star Trek universe. Maris, the GV (Google Ventures) founder/former-CEO, has raised $150 million for the project that will focus on various investments. The fund will be run directly by Maris and primarily based out of San Diego.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2017 | BloomAPI | Seed Round | 2.4M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 10/2020 | Dialpad | Series E | 100M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 2/2022 | Cohere | Series B | 0 |
| 12/2021 | Verge Genomics | Series B | 98M |
| 7/2019 | Freenome | Series B | 160M |
| 4/2021 | Current Health | Series B | 43M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 8/2017 | Freenome | Series A | 7M |
| 3/2020 | Culture Biosciences | Series A | 0 |
| 11/2020 | WithMe Health | Series B | 25M |
| 11/2019 | Legacy | Seed Round | 3.5M |
| 6/2019 | Legacy | Pre Seed Round | 1.5M |
| 9/2021 | TrialSpark | Series C | 156M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 4/2019 | Embark | Series A | 12M |
| 8/2017 | Coinbase | Series D | 108.1M |
| 12/2021 | Exai Bio | Series A | 67.5M |
| 5/2019 | MedCrypt | Series A | 6.3M |
| 12/2020 | Octave Bioscience | Series B | 32M |
| 2/2023 | Faro Health | Series A | 0 |
| 7/2020 | Glympse Bio | Series B | 46.7M |
| 10/2021 | Wise Systems | Series C | 0 |
| 8/2022 | Spectral | Venture Round | 0 |
| 8/2022 | Inworld AI | Series A | 0 |
| 9/2017 | Dialpad | Series C | 17M |
| 6/2023 | Delve Bio | Series A | 0 |
| 7/2018 | Dialpad | Series D | 50M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 7/2022 | Swadesh | Pre Seed Round | 2.3M |
| 3/2022 | Nucleai | Series B | 0 |
| 10/2022 | Stairwell | Series B | 0 |
| 2/2019 | Culture Biosciences | Venture Round | 0 |
| 11/2021 | Mekonos | Series A | 0 |
| 11/2018 | Primer | Series B | 40M |
| 11/2022 | MedCrypt | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 4/2018 | Vineti | Series B | 33.5M |
| 2/2021 | Miroculus | Series B | 45M |
| 11/2021 | MedArrive | Series A | 0 |
| 8/2017 | Auris Health | Series D | 0 |
| 12/2021 | Dialpad | Series F | 0 |
| 4/2022 | Parallel Finance | Venture Round | 0 |
| 5/2022 | Character Biosciences | Series A | 0 |
| 2/2019 | Teckro | Series C | 0 |
| 6/2021 | Primer | Series C | 0 |
| 3/2022 | SandboxAQ | Series D | - |
| 5/2020 | Phaidra | Seed Round | 1.5M |
| 4/2023 | Function Oncology | Series A | 28M |
| 3/2021 | Meatable | Series A | 47M |
| 5/2021 | Phaidra | Seed Round | 0 |
| 7/2022 | Phaidra | Series A | 0 |
| 12/2021 | ONI | Series B | 75M |
| 7/2017 | Embark | Seed Round | 5.5M |
| 10/2018 | Nusano | Series A | - |
| 7/2020 | Sema4 | Series C | 121M |
| 2/2022 | Syllable | Series C | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 10/2017 | Lime | Series B | 50M |
| 7/2018 | Metromile | Series E | 90M |
| 7/2018 | Cue | Series B | 0 |
| 3/2022 | Satellite Bio | Series A | 0 |
| 2/2020 | Vineti | Series C | 35M |
| 7/2022 | BigHat Biosciences | Series B | 0 |
| 9/2021 | Cohere | Series A | 40M |
| 10/2020 | Vineti | Series C | 33M |
| 1/2021 | EQRx | Series B | 500M |
| 8/2019 | Sema4 | Series B | 120M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 6/2021 | Syllable | Series B | 28M |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 1/2022 | Metaphysic | Venture Round | 7.5M |
| 6/2021 | ImmuneID | Series A | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 6/2023 | AltPep | Series B | 0 |
| 7/2019 | Cradle Genomics | Series A | 0 |
| 6/2021 | Faro | Series A | 15M |
| 8/2020 | Freenome | Series C | 270M |
| 5/2022 | Legacy | Series B | 25M |
| 12/2019 | XOKind | Seed Round | 3.3M |
| 8/2017 | Teckro | Series B | 10M |
| 12/2019 | XOKind | Pre Seed Round | 3.6M |
| 2/2023 | Faro | Series A | 20M |
| 5/2017 | Kobalt | Series D | 75M |
| 10/2017 | Kobalt | Series D | 14M |
| 10/2021 | Gretel | Series B | 0 |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 12/2021 | Nodexus | Series A | 30M |
| 10/2021 | ScienceIO | Seed Round | 0 |
| 7/2020 | Evidation Health | Series D | 45M |
| 12/2021 | Freenome | Series D | 300M |
| 10/2017 | Dave | Series A | 13.3M |
| 7/2018 | Octave Bioscience | Series A | 14M |
| 2/2018 | Celularity | Series A | 250M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 1/2019 | Ciitizen | Series A | 17M |
| 1/2020 | EQRx | Series A | 200M |
| 6/2022 | Manifold Bio | Series A | 0 |
| 9/2018 | Fulcrum Therapeutics | Series B | 80M |
| 10/2021 | Culture Biosciences | Series B | 0 |
| 4/2023 | Function Oncology | Series A | 0 |
| 2/2023 | Faro Health | Series A | 0 |
| 1/2023 | Forward Networks | Series D | 0 |
| 11/2022 | MedCrypt | Series B | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2022 | Stairwell | Series B | 0 |
| 10/2022 | Nested Therapeutics | Series A | 0 |
| 9/2022 | Autobahn Therapeutics | Venture Round | 0 |
| 8/2022 | Spectral | Venture Round | 0 |
| 8/2022 | Inworld AI | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
